Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Glaukos Corporation (GKOS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret the information. Glaukos is an ophthalmic pharmaceutical and medical technology company focused on therapies for glaucoma, corneal disorders, and retinal diseases, and its filings provide detailed insight into this business.
Through periodic reports such as Forms 10-Q and 10-K, investors can review Glaukos’ net sales, segment performance in glaucoma and corneal health, gross margins, operating expenses, and net income or loss. These filings also describe risk factors relevant to its ophthalmic device and pharmaceutical portfolio, including regulatory requirements, clinical trial processes, reimbursement dynamics, manufacturing considerations, and intellectual property matters referenced in the company’s public communications.
Current reports on Form 8-K capture material events such as quarterly and annual financial results, preliminary net sales updates, and investor presentations. For example, Glaukos has filed 8-Ks to furnish press releases on second and third quarter financial results, preliminary unaudited net sales for a fiscal year, and investor presentation materials. These documents often include or reference revenue guidance ranges and explanations of non-GAAP financial measures and constant currency net sales metrics.
On Stock Titan, AI-generated summaries help explain the key points of lengthy filings, highlighting items such as revenue trends, segment details, and notable risk disclosures without replacing the full text. Real-time updates from EDGAR ensure new Glaukos filings appear promptly, while dedicated sections make it straightforward to locate quarterly reports, annual reports, and current reports tied to material announcements.
For users analyzing GKOS, this page offers a structured view of Glaukos’ SEC reporting history alongside AI insights that clarify complex financial and regulatory information related to its ophthalmic pharmaceutical and medical technology activities.
Glaukos Corp Chairman and CEO Thomas William Burns reported a tax-withholding share disposition related to equity compensation. On the vesting of previously granted restricted stock units, 2,744 shares of common stock were withheld by the company at $105.23 per share to cover his tax obligations. After this non-market transaction, he directly holds 239,707 common shares and also reports indirect ownership through several Burns family trusts. The filing also notes 59,399 restricted stock units that remain unvested and undelivered.
Glaukos Corp Chief Development Officer Tomas Navratil reported routine tax-related share withholdings tied to restricted stock unit vesting. On March 23, 2026, 2,628 shares of common stock were withheld at $106.84 per share, leaving 71,003 shares directly held. On March 24, 2026, an additional 2,546 shares were withheld at $105.23 per share, leaving 68,457 shares directly held. These dispositions were made to satisfy tax withholding obligations on previously granted restricted stock units rather than as open-market sales. Footnotes state his holdings include 29,840 and 24,705 restricted stock units from prior grants that have not yet vested or been delivered.
Glaukos Corp Senior Vice President and Chief Financial Officer Alex R. Thurman reported recent stock transactions. On March 24, he sold 1,521 shares of common stock in an open-market trade at an average price of $105.24 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025. Following these transactions, he directly holds 44,478 shares of common stock, and his holdings also include restricted stock units that have not yet vested or been delivered, as described in the footnotes. Additional dispositions of 2,020 shares on March 24 and 1,230 shares on March 23 were shares withheld by the company to cover tax obligations upon vesting of restricted stock units granted in 2023 and 2022.
GLAUKOS Corp president and COO Joseph E. Gilliam reported routine share dispositions tied to tax withholding, not open-market sales. On March 23 and 24, 2026, a total of 15,118 shares of common stock were withheld by the company to cover his tax obligations upon restricted stock unit vesting. Following these transactions, he continues to hold 72,540 shares of common stock directly. Footnotes indicate his holdings also include unvested restricted stock units from prior grants.
GKOS reports a proposed sale of 2,511 shares of Common Stock tied to a restricted stock vesting on 03/24/2026. The filing lists the sale as Compensation and shows prior dispositions of 625 shares on 03/17/2026 and 1,521 shares on 03/24/2026.
Glaukos Corp. notified proposed affiliate sales of Common Stock tied to recent compensation vesting. The notice lists 1,521 shares of Common Stock eligible for sale following a restricted stock vesting on 03/22/2026 and shows a prior sale by Alex Thurman of 625 shares on 03/17/2026 for $61,968.75.
The filing identifies the sales as compensation-related and lists Fidelity Brokerage Services LLC as the broker. This is a routine affiliate disclosure of proposed and recent transactions under applicable resale rules.
Glaukos Corp chief development officer Tomas Navratil reported a combination of tax withholding and open-market sales of company stock. On March 16, 2026, 958 shares of common stock were withheld to cover tax obligations tied to the vesting of previously granted restricted stock units.
On the same date, he sold a total of 1,031 common shares in open-market transactions at weighted average prices of $97.33, $98.21, and $99.05 per share, under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly beneficially owns 73,631 shares of Glaukos common stock, including 35,687 restricted stock units that have not yet vested or been delivered.
GLAUKOS Corp senior vice president and chief financial officer Alex R. Thurman reported two recent stock transactions. On March 17, 2026, he executed an open‑market sale of 625 shares of common stock at $99.15 per share. On March 16, 2026, 614 shares were disposed of to cover tax withholding obligations tied to vesting of restricted stock units granted on March 14, 2024, which is a non‑market event. After these transactions, he directly held 49,249 shares of common stock, including 12,512 restricted stock units that have not yet vested or been delivered and 167 stock units acquired through the employee stock purchase plan. The sale was carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 15, 2025, indicating it was scheduled in advance.
GLAUKOS Corp’s President & COO Joseph E. Gilliam reported a routine tax-related share disposition. On the vesting of previously granted restricted stock units, 1,189 shares of common stock were withheld by the company to cover his tax obligations.
After this withholding, Gilliam directly holds 87,658 shares of GLAUKOS common stock, which the disclosure states includes 53,986 restricted stock units that are granted but not yet vested or delivered. This event reflects compensation and tax mechanics rather than an open‑market stock sale.
GLAUKOS Corp chairman and CEO Thomas William Burns reported a routine tax-related share disposition. On March 16, 2,801 shares of common stock were withheld by the company at $98.94 per share to satisfy tax obligations tied to previously granted restricted stock units.
After this withholding, Burns directly holds 242,451 common shares and also has indirect holdings through several family-related trusts. The disclosure notes 64,610 restricted stock units that have not yet vested or been delivered, indicating additional potential future share delivery subject to vesting conditions.